Other substances

Tetrandrine

A bis-benzylisoquinoline alkaloid.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Tetrandrine is a bis-benzylisoquinoline alkaloid. It has been reported to act as a calcium channel blocker and shown to possess anti-SARS-CoV-2 activity in vitro (He et al., 2021).

Tetrandrine on DrugBank
Tetrandrine on PubChem
Tetrandrine on Wikipedia

Synonyms

SC182; Fanchinine; Sinomenine A; Hanfangchin A

CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Preprint In vitro Screening	HeLa-ACE2 cells			Jun/16/2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 Small molecule In vitro Screening	Vero cells	5.09		Nov/25/2020
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing Small molecule In vitro Screening	Vero E6 cells	42.78		Jul/24/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells		higher IC50 value in Calu-3 cells than VERO E6 cells	May/12/2020
Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products Small molecule In vitro Mechanism	in vitro binding assay; 293T-ACE2 cells; Calu-3 cells; A549 cells; Vero E6 cells; (HIV-1) SARS-CoV-2 Spike (D614/G614/B.1.1.7/B.1.351); SARS-CoV-2 live virus	13.49	Tetrandrine inhibited lentiviral SARS-CoV-2 Spike-pseudotyped virus infection in 293T-ACE2 (EC50 of 0.9 μM or lower, SI >55), Calu-3 and A549 cells. It displayed efficacy also against pseudoviruses with Spike protein of G614, B.1.1.7, B.1.351, SARS, and MERS viruses/strains. The experimental findings suggest that the compound blocks coronavirus entry into host cells by inhibition of calcium ion channels. The compound was also shown to protect Vero E6 cells from SARS-CoV-2 live virus-induced cytopathogenic effect.	Mar/23/2021

AI-suggested references

Link	Publication date
Nature-derived hit, lead, and drug-like small molecules: Current status and future aspects against key target proteins of Coronaviruses.	Jul/08/2021
Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine.	May/08/2021
Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic.	Aug/29/2020
Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2	Dec/09/2021
Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19	Sep/16/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04308317	Tetrandrine Tablets Used in the Treatment of COVID-19	Unknown status	Phase 4	Mar/05/2020	May/01/2021
Alternative id - TT-NPC Interventions - Drug: Tetrandrine Study type - Interventional Study results - No Results Available Locations - Tetrandrine Tablets, Jinhua, Zhejiang, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Survival rate\|body temperature

Export (.csv)